|
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
|
Jul 2015
|
Oncologist
|
myelodysplastic syndromes (MDS)
|
|
Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights
|
Dec 2016
|
Oncol Rev
|
myelodysplastic syndromes (MDS)
|
|
Stem cell origin of myelodysplastic syndromes
|
Dec 2013
|
Oncogene
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes in children: where are we today?
|
Jan 2012
|
Ochsner J
|
myelodysplastic syndromes (MDS)
|
|
Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
|
Jan 2012
|
Neoplasma
|
myelodysplastic syndromes (MDS)
|
|
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|
Aug 2020
|
Nature Medicine
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic Syndromes Treatment (PDQ®): Patient Version
|
Mar 2019
|
National Cancer Institute
|
myelodysplastic syndromes (MDS)
|
|
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
|
Jan 2015
|
Nat Commun.
|
myelodysplastic syndromes (MDS)
|
|
Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells
|
Mar 2015
|
Nat Biotechnol
|
myelodysplastic syndromes (MDS)
|
|
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
|
Apr 2017
|
N Engl J Med
|
aplastic anemia
|
